Incyte says SCRATCH-AD trial meets primary endpoint

Incyte announced new data from the Phase 2 SCRATCH-AD trial evaluating the short-term clinical benefits of Opzelura cream 1.5% to control pruritus and reduce disease severity in adult patients with atopic dermatitis, the most common type of eczema. These data were featured in a poster presentation at the Revolutionizing Atopic Dermatitis Conference, held from April 29-May 1 in Washington, D.C. Results showed that patients with AD treated with Opzelura experienced a rapid and substantial improvement in itch, which was sustained and further improved through 28 days of treatment. Specifically, the study met its primary endpoint with Opzelura-treated patients experiencing a mean (SE) -3.4 (0.28) reduction in itch from baseline at Day 2 as measured by the peak pruritus numerical rating scale (PP-NRS; an 11-point scale evaluating the peak intensity of itch over the course of 24 hours). Itch reduction was observed beginning as early as 15 minutes (2.3 [0.35]) as measured by modified PP-NRS, and the change from baseline, observed at four hours after the first application of Opzelura, was 4.2 mPP-NRS [0.31]. "AD is a chronic, immune-mediated skin condition that can be difficult to manage and causes disruptive and persistent symptoms like itch that can greatly affect patients’ everyday lives," said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte. "We are pleased that the SCRATCH-AD results further emphasize the rapid impact of Opzelura on itch reduction and reinforce its profile as an effective, well-tolerated topical non-steroidal treatment for AD."